CD248 and bladder transitional cell carcinoma: CD248 mutation was linked to better prognosis in OV patients in terms of disease-free survival (P = 0.0178) (Figure 4D), whereas CD248 mutation was linked to poor prognosis in BLCA patients in terms of disease-free survival (P = 0.0422) (Figure 4E) and overall survival (P = 0.0284) (Figure 4F).